Top Picks: Accredited Activities

top-picks-wang-2022-02-17.jpg

Treatment Selection: A Focus on Prognostic Indicators

Eunice S. Wang, MD

Review of evolving treatment approaches in pediatric patients with newly diagnosed AML

Review of evolving treatment approaches in pediatric patients with newly diagnosed AML

Richard Aplenc, MD, PhD, MSCE

Secondary AML Treatment in Pediatric Patients

Secondary AML Treatment in Pediatric Patients

E. Anders Kolb, MD

Most Viewed

New Uses for Hypomethylating Agents (HMAs)

New Uses for Hypomethylating Agents (HMAs)

Brian A. Jonas, MD, PhD, FACP

What are the latest updates in the Phase 3 study of gilteritinib and AZA vs AZA alone for ND FLT-3 AML in patients ineligible for induction chemotherapy?

What are the latest updates in the Phase 3 study of gilteritinib and AZA vs AZA alone for ND FLT-3 AML in patients ineligible for induction chemotherapy?

Eunice S. Wang, MD

A Focus on Prognostic Indicators for Treatment in Patients with AML?

A Focus on Prognostic Indicators for Treatment in Patients with AML?

Eunice S. Wang, MD
What is the best approach to the therapy of patients with P53-mutated AML?

MediCom Oncology Links

Please visit these other members of the MediCom Oncology family of sites.

Managing MDS Managing Myeloma Managing MPN The Practical Oncologist Managing Lymphoma